A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice

Pinheiro, Carina S., Ribeiro, Ana Paula Dias, Cardoso, Fernanda C., Martins, Vicente P., Figueiredo, Barbara C. P., Assis, Natan R. G., Morais, Suellen B., Caliari, Marcelo V., Loukas, Alex and Oliveira, Sergio C. (2014) A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice. Parasite Immunology, Accepted Article 7: 1-23. doi:10.1111/pim.12118

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
ParasiteImmunol.pdf Full text (open access) application/pdf 649.18KB 0

Author Pinheiro, Carina S.
Ribeiro, Ana Paula Dias
Cardoso, Fernanda C.
Martins, Vicente P.
Figueiredo, Barbara C. P.
Assis, Natan R. G.
Morais, Suellen B.
Caliari, Marcelo V.
Loukas, Alex
Oliveira, Sergio C.
Title A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice
Formatted title
A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice
Journal name Parasite Immunology   Check publisher's open access policy
ISSN 0141-9838
1365-3024
Publication date 2014-04-22
Year available 2014
Sub-type Article (original research)
DOI 10.1111/pim.12118
Open Access Status File (Author Post-print)
Volume Accepted Article
Issue 7
Start page 1
End page 23
Total pages 23
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing Ltd.
Language eng
Formatted abstract
Schistosoma mansoni is a blood fluke parasite responsible for schistosomiasis. The best long-term strategy to control schistosomiasis is through immunization combined with drug treatment. In this study, we cloned, expressed and purified SmTSP-2 fused to the N- and C-terminal halves of Sm29 and tested these chimeras as vaccine candidates using an adjuvant approved to be used in humans. The results demonstrated that vaccination with SmTSP-2 fused to N- or C- terminus of Sm29 induced reduction in worm burden and liver pathology when compared to control animals. Additionally, we detected high levels of mouse specific IgG, IgG1 and IgG2a against both chimeras and significant amounts of IFN-γ and TNF-α and no IL-4. Finally, studies with sera from patients resistant to infection and living in schistosomiasis endemic areas revealed high levels of specific IgG to both chimeras when compare to healthy individuals. In conclusion, SmTSP-2/Sm29 chimeras tested here induced partial protection against infection and might be a potential vaccine candidate.
Keyword Schistosoma mansoni
Vaccine
Sm29
TSP-2
Schistosoma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Accepted manuscript online: 22 APR 2014

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
Institute for Molecular Bioscience - Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 14 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 27 Apr 2014, 00:25:13 EST by Fernanda Caldas Cardoso on behalf of Institute for Molecular Bioscience